治疗后FAPI PET信号逆转有多快?评估高血压心脏损伤与纤维化小鼠的FAPI PET信号
本研究在小鼠血管紧张素II/去氧肾上腺素输注模型中纵向行68Ga-FAPI-46 PET/CT,发现心肌FAPI摄取在1周达峰,肝脏摄取在2周达峰,停药后心肝PET信号迅速降至不可辨水平;FAPI信号早于射血分数下降出现,停药3周后纤维化较未恢复组显著减少。
要点
- 小鼠输注Ang-II/PE后心肌68Ga-FAPI-46摄取1周达峰,肝脏摄取2周达峰、4周显著下降。
- 停药后心脏和肝脏PET信号早期即降至不可辨水平,3周恢复后纤维化较1周即处死组显著减少。
- 心脏FAPI信号先于射血分数下降出现,提示可用于早期检测心脏重构中的纤维化。
核心结论
- Ang-II/PE停药后PET信号快速下降,表明FAPI PET能有效显示FAP表达的动态变化,是快速评估靶向活化成纤维细胞治疗反应的有价值工具。
- 心脏FAPI信号先于心肌功能改变出现,提示FAPI PET可检测导致心力衰竭的心脏重构中的早期纤维化。
- FAPI PET也可能显示心脏性肝硬化,这是心脏疾病的一种严重并发症。
研究设计与样本
- 小鼠植入微泵输注血管紧张素II/去氧肾上腺素(Ang-II/PE)6周,对照组输注生理盐水,纵向行68Ga-FAPI-46 PET/CT扫描。
- 在预设时间点行68Ga-FAPI-46生物分布研究,离体测量主要器官FAPI摄取。
- 一组动物分别在1周和2周停止Ang-II/PE输注以评估心肌和肝脏FAPI PET信号的可逆性。
- 通过超声心动图评估左室结构和功能,组织学评估组织纤维化,免疫组化评估FAP表达。
主要发现
- 治疗小鼠心肌68Ga-FAPI-46摄取显著,于1周达峰。
- 肝脏68Ga-FAPI-46摄取也增加,于2周达峰,4周时显著下降。
- Ang-II/PE停药后早期,心脏和肝脏PET信号降至不可辨水平。
- 停泵3周后,先前暴露于Ang-II/PE 1周的小鼠心脏纤维化较Ang-II/PE输注1周后立即处死、未经3周恢复期的小鼠显著减少。
- 共注射过量未标记FAPI-46降低了心脏、肝脏和肾脏的摄取;尽管1周时左室壁厚度增加,射血分数初期保持稳定,但4周时显著下降。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Reactive fibrosis is a complex response to chronic myocardial insults, contributing to heart failure progression. Fibroblast activation protein inhibitor (FAPI) PET shows promise in distinguishing active from established fibrosis. Although antifibrotic therapies may improve left ventricular (LV) function in preclinical studies, their clinical application is limited by the lack of noninvasive imaging methods to assess fibrosis regression. This study investigates the potential of FAPI PET to track the therapeutic transition of activated fibroblast activation protein (FAP)-positive fibroblasts toward a FAP-negative phenotype. Methods: Mice were implanted with minipumps, infused with angiotensin-II/phenylephrine (Ang-II/PE) for 6 wk and scanned with 68Ga-FAPI-46 PET/CT longitudinally. Control mice received saline. 68Ga-FAPI-46 biodistribution studies were conducted at preselected time points, and FAPI uptake in the major organs was measured ex vivo. To assess the potential reversibility of the FAPI PET signal in the myocardium and liver, Ang-II/PE infusion was discontinued in a group of animals at 1 and 2 wk, respectively. LV structural and functional changes were assessed via echocardiography, tissue fibrosis via histology, and FAP expression via immunohistochemistry. Results: Significant 68Ga-FAPI-46 uptake in the myocardium of treated mice peaked at 1 wk. An increase of 68Ga-FAPI-46 uptake was also observed in the liver, peaking at 2 wk, and decreased significantly at 4 wk. The PET signal declined to an indiscernible level in the heart and liver early after Ang-II/PE withdrawal. Three weeks after the removal of the minipumps, the hearts of mice previously exposed to Ang-II/PE for 1 wk exhibited a significant reduction in fibrosis compared with mice that were sacrificed immediately after 1 wk of Ang-II/PE infusion, without the 3-wk recovery period. Coinjection with excess unlabeled FAPI-46 reduced uptake in the heart, liver, and kidneys. Despite an increase in LV wall thickness at 1 wk, the ejection fraction remained stable initially but dropped significantly by 4 wk. Conclusion: The rapid decline in PET signal after Ang-II/PE withdrawal shows that FAPI PET effectively visualizes dynamic changes in FAP expression, making it a valuable tool for quickly assessing treatment responses targeting activated fibroblasts. The cardiac FAPI signal precedes functional myocardial changes, indicating that FAPI PET could detect early fibrosis in cardiac remodeling leading to heart failure. FAPI PET may also visualize cardiac cirrhosis, a serious complication of cardiac disorders.
引用
- Hosseini A, Haj-Yehia E, Korste S, et al. How Rapidly Does the FAPI PET Signal Reverse Following Therapy? Assessing the FAPI PET Signal in Hypertensive Cardiac Injury and Fibrosis in Mice. J Nucl Med. 2025. PMID: 40935615. doi:10.2967/jnumed.124.268860
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。